Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis

被引:34
|
作者
Raynauld, JP
Goldsmith, CH
Bellamy, N
Torrance, GW
Polisson, R
Belovich, D
Pericak, D
Tugwell, P
机构
[1] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] St Josephs Healthcare, Ctr Evaluat Med, Hamilton, ON, Canada
[4] Univ Queensland, CONROD, Fac Hlth Sci, Brisbane, Qld, Australia
[5] Innovus Res Inc, Burlington, ON, Canada
[6] Genzyme Corp, Cambridge, MA USA
[7] Univ Ottawa, Ctr Global Hlth, Inst Populat Hlth, Ottawa, ON, Canada
关键词
hylan G-F 20; osteoarthritis; repeat courses; effectiveness;
D O I
10.1016/j.joca.2004.10.018
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objective: To compare the effectiveness and safety of repeat treatment with hylan G-F 20 based on data from a randomized, controlled trial [Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17]. The hypotheses tested were whether the single-course and repeat-course subgroups would be superior to appropriate care and not different from each other. Method: A total of 255 patients with knee osteoarthritis were randomized to "appropriate care with hylan G-F 20" or "appropriate care without hylan G-F 20". The hylan G-F 20 group was partitioned into two subgroups: (1) patients who received a single course of hylan G-F 20; and (2) patients who received two or more courses of hylan G-F 20. Results: For the primary effectiveness measure, change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score as a percent of baseline, the single-course subgroup improved by 41%, the repeat-course subgroup by 35%, and the appropriate care group by 14%. Both subgroups improved significantly more than the appropriate care group (P < 0.05), and were not statistically significantly different from each other (70% power to detect a 20% difference). Secondary effectiveness measures showed similar results. In the repeat-course subgroup, no statistically significant differences were found in the number of local adverse events, the number of patients with local adverse events, or arthrocentesis rates between the first and repeat courses of treatment. Conclusions: Although the study was neither designed nor powered to examine repeat treatment, this a posteriori analysis provides support for a favorable effectiveness and safety profile of hylan G-F 20 in repeat course patients. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码:111 / 119
页数:9
相关论文
共 50 条
  • [1] Effectiveness and safety of hylan G-F 20 compared to steroid injections in patients with knee osteoarthritis.
    Raynauld, JP
    Olszynski, WP
    Goldsmith, CH
    Torrance, GW
    Bellamy, N
    Polisson, R
    Pericak, D
    Walker, V
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S484 - S484
  • [2] THE EFFECTIVENESS AND COST-EFFECTIVENESS OF HYLAN G-F 20 IN OSTEOARTHRITIS OF THE KNEE
    Kostyuk, A.
    Almadiyeva, A.
    Akanov, A.
    VALUE IN HEALTH, 2015, 18 (07) : A647 - A647
  • [3] Functional Improvement with Hylan G-F 20 in Patients with Knee Osteoarthritis
    Brander, Victoria A.
    Stadler, Teresa S.
    PHYSICIAN AND SPORTSMEDICINE, 2009, 37 (03): : 38 - 48
  • [4] Viscosupplementation for knee osteoarthritis: a focus on Hylan G-F 20
    Webb, David
    Naidoo, Poobalan
    ORTHOPEDIC RESEARCH AND REVIEWS, 2018, 10 : 73 - 81
  • [5] Risk Factors for Knee Arthroplasty in Patients with Knee Osteoarthritis Treated with Hylan G-F 20
    Runa, Maria
    Ong, Kevin
    Lau, Edmund
    Daley, William
    Altman, Roy
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2018, 50 (05): : 679 - 679
  • [6] HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS (OA): A COCHRANE REVIEW
    Bellamy, N., Jr.
    Campbell, J.
    Gee, T.
    Robinson, V.
    Wells, G.
    Bourne, R.
    RHEUMATOLOGY, 2004, 43 : 63 - 64
  • [7] Intrarticular Hylan G-F 20 (Synvisc)® in the treatment of patients with osteoarthritis of the knee.
    Sharlati, J
    Hatef, M
    Jokar, M
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 3 - 3
  • [8] Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis - A systematic review
    Espallargues, M
    Pons, JMV
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2003, 19 (01) : 41 - 56
  • [9] Hylan G-F 20 for knee Osteoarthritis (OA): A Cochrane review.
    Bellamy, N
    Campbell, J
    Gee, T
    Robinson, V
    Wells, G
    Bourne, RB
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S697 - S697
  • [10] Viscosupplementation with hylan G-F 20 in patients with osteoarthrosis of the knee
    Bert, Jack M.
    Waddell, David D.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2010, 3 (03) : 127 - 132